CytomX Therapeutics (CTMX) Current Leases (2019 - 2025)
Historic Current Leases for CytomX Therapeutics (CTMX) over the last 7 years, with Q3 2025 value amounting to $5.6 million.
- CytomX Therapeutics' Current Leases rose 1189.76% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 1189.76%. This contributed to the annual value of $5.1 million for FY2024, which is 1211.59% up from last year.
- Per CytomX Therapeutics' latest filing, its Current Leases stood at $5.6 million for Q3 2025, which was up 1189.76% from $5.4 million recorded in Q2 2025.
- CytomX Therapeutics' 5-year Current Leases high stood at $5.6 million for Q3 2025, and its period low was $3.6 million during Q4 2021.
- Over the past 5 years, CytomX Therapeutics' median Current Leases value was $4.5 million (recorded in 2023), while the average stood at $4.6 million.
- In the last 5 years, CytomX Therapeutics' Current Leases skyrocketed by 1282.48% in 2022 and then soared by 1189.76% in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Current Leases stood at $3.6 million in 2021, then rose by 12.82% to $4.1 million in 2022, then rose by 12.42% to $4.6 million in 2023, then increased by 12.12% to $5.1 million in 2024, then grew by 8.77% to $5.6 million in 2025.
- Its Current Leases was $5.6 million in Q3 2025, compared to $5.4 million in Q2 2025 and $5.3 million in Q1 2025.